Equibles does not estimate personal net worth.
Get an email with a short summary when BeOne Medicines Ltd. publishes a filing, an earnings call transcript or a press release.
Get ONC alertsJohn Oyler is recorded as CEO at BeOne Medicines Ltd. (ONC). John Oyler has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for BeOne Medicines Ltd. on August 5, 2026. BeOne Medicines Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BeOne Medicines Ltd. includes Mr. John V. Oyler (CEO and Board Member), John V. Oyler (Chairman), Mr. Aaron Rosenberg (CFO) and 7 others.
“Q2 was a very strong quarter across every dimension of our business. From a financial perspective, we achieved $1.7 billion in total revenues and $2.05 in GAAP earnings per ADS.”
“So, yes, we have brought a lot of molecules into the clinic, and it is our aspiration to bring additional internally discovered as well as some partnered molecules into the clinic.”
“Q4 marked another solid quarter of execution and a really strong finish to the year. And what a year it was. 2025 certainly lived up to its promise as a year of inflection for B1.”
“The third quarter marked another strong quarter of execution. From a financial perspective, revenue reached $1.4 billion, which represents 41% year-on-year growth.”
Biotechnology · Healthcare
CEO
